SCHEMBL29993547

SCHEMBL29993547

CC(=O)c1ccnc(Oc2ccc(C)c(C)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ HAO1 Q9UJM8 1/20 0.43
▸ RAB9A P51151 2/20 0.41
▸ LOXL2 Q9Y4K0 2/20 0.41
▸ HPGD P15428 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ GFER P55789 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ GRM2 Q14416 1/20 0.38
▸ CYSLTR1 Q9Y271 1/20 0.38
▸ KCNK3 O14649 1/20 0.38
▸ KCNK9 Q9NPC2 1/20 0.38
▸ ESRRA P11474 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21581580 0.78 HAO1 (0.50) KMT2AMEN1HAO1RAB9AHPGD
SCHEMBL14548335 0.76 HPGD (0.70) KMT2AMEN1RAB9AHPGDMAPT
SCHEMBL29992874 0.75 SMN1; SMN2 (0.47) KMT2AMEN1RAB9AMAPTSMN1; SMN2
SCHEMBL21580663 0.75 HAO1 (0.51) KMT2AMEN1HAO1RAB9ALOXL2
SCHEMBL29640109 0.74 KCNK3 (0.55) KMT2AMEN1LOXL2SMN1; SMN2LMNA
SCHEMBL12640026 0.74 KCNK3 (0.55) KMT2AMEN1LOXL2SMN1; SMN2LMNA
SCHEMBL1286279 0.72 KMO (0.49) KMT2AMEN1HAO1HPGDMAPT
SCHEMBL18181773 0.71 DRD1 (0.52) KMT2AMEN1HAO1RAB9AHPGD
SCHEMBL14480077 0.71 CREBBP (0.50) KMT2AMEN1MAPTSMN1; SMN2L3MBTL1
SCHEMBL31085012 0.70 ACACB (0.46) KMT2AMEN1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 — — US claimed
US-20250368595-A1 NOVEL MOLECULES Xeniopro GmbH (DE) 2025-12-04 — — US disclosed
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY Xeniopro GmbH (DE) 2023-05-11 — — US disclosed
US-20220249500-A1 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY Xeniopro GmbH (DE) 2022-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249500-A1 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY AHR, MUSK, TYR KMT2A 762/4885MEN1 4794/4885HAO1 739/4885
US-20250368595-A1 NOVEL MOLECULES MUSK, IKZF3, TYR KMT2A 957/4885MEN1 4589/4885HAO1 2858/4885
US-20230141913-A2 PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY AHR, MUSK, TYR KMT2A 762/4885MEN1 4794/4885HAO1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback